Influenza Diagnostic tests with specificity and high sensitivity are major developments in influenza diagnostics over recent years. Reverse transcription-polymerase chain reaction (RT-PCR) and Nucleic acid labeling detection tests have greatly improved the ability to detect respiratory viruses. Additionally, molecular tests for influenza are mainly focused on the detection of specific known pathogens by NATs. NATs have several advantages over other existing diagnostic tools. They potentially can detect low levels of all-known influenza pathogens in clinical specimens, do not depend on the viability of the target microbe, and can provide results within a clinically relevant time frame. Influenza Diagnostics Market size is projected to reach USD 1.3 billion in 2027 from an estimated USD 0.86 billion in 2021, growing at a CAGR of 7.4% globally. Market analysis, sizing, and forecast of the influenza diagnostics market are covered in the report. The country-level assessment of th...